SG&A Efficiency Analysis: Comparing Dr. Reddy's Laboratories Limited and Iovance Biotherapeutics, Inc.

SG&A Efficiency: Pharma vs. Biotech

__timestampDr. Reddy's Laboratories LimitedIovance Biotherapeutics, Inc.
Wednesday, January 1, 2014387830000009335772
Thursday, January 1, 20154258500000012390000
Friday, January 1, 20164570200000025602000
Sunday, January 1, 20174637200000021262000
Monday, January 1, 20184691000000028430000
Tuesday, January 1, 20194889000000040849000
Wednesday, January 1, 20205012900000060210000
Friday, January 1, 20215455900000083664000
Saturday, January 1, 202262081000000104097000
Sunday, January 1, 2023105931000000106916000
Monday, January 1, 202477201000000
Loading chart...

Igniting the spark of knowledge

SG&A Efficiency: A Tale of Two Companies

In the world of pharmaceuticals and biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and operational efficiency. Dr. Reddy's Laboratories Limited, a global pharmaceutical giant, and Iovance Biotherapeutics, Inc., a pioneering biotech firm, offer a fascinating contrast in SG&A management from 2014 to 2023.

Dr. Reddy's Laboratories has seen a steady increase in SG&A expenses, peaking at over 105% growth by 2023 compared to 2014. This reflects their expansive global operations and strategic investments. In contrast, Iovance Biotherapeutics, with a more focused niche, has experienced a significant rise in SG&A expenses, growing by approximately 1,045% over the same period, highlighting their aggressive growth strategy.

While Dr. Reddy's shows a consistent upward trend, Iovance's data for 2024 is missing, leaving room for speculation on their future trajectory.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025